## **Core Concept**
The question tests the understanding of antiplatelet drugs, specifically those targeting glycoproteins on the platelet surface. Glycoprotein IIb/IIIa (Gp IIb/IIIa) is a receptor on platelets that plays a critical role in platelet aggregation. Drugs that inhibit this receptor prevent platelet aggregation, which is beneficial in conditions like acute coronary syndromes.

## **Why the Correct Answer is Right**
The correct answer, **Abciximab**, is a monoclonal antibody that binds to the Gp IIb/IIIa receptor on platelets, inhibiting fibrinogen binding and subsequent platelet aggregation. This action prevents thrombus formation and is particularly useful in acute coronary syndromes and during percutaneous coronary interventions (PCI). Abciximab is known for its potent antiplatelet effects.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Aspirin works by inhibiting cyclooxygenase (COX) enzymes, which are involved in the production of thromboxane A2, a potent platelet activator. It does not directly inhibit Gp IIb/IIIa.
- **Option B:** Clopidogrel is a P2Y12 receptor antagonist that prevents ADP-mediated platelet activation and aggregation but does not directly affect Gp IIb/IIIa.
- **Option D:** Tirofiban is a non-peptide tyrosine derivative that also inhibits the Gp IIb/IIIa receptor but is not a monoclonal antibody like Abciximab; it is a small molecule.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that drugs inhibiting Gp IIb/IIIa, like Abciximab, Tirofiban, and Eptifibatide, are critical in the management of acute coronary syndromes and during PCI to prevent thrombotic complications. Their use requires careful monitoring due to the risk of bleeding.

## **Correct Answer:** . Abciximab